LCM
TOVX icon

Landscape Capital Management’s Theriva Biologics TOVX Stock Holding History

Landscape Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6
Closed -$34K – 480
2017
Q1 		$34K Buy
+6
New +$41.9K ﹤0.01% 496

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Landscape Capital Management's TOVX Position: Q2 2017 in Review

Landscape Capital Management sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 6 shares — an estimated $34K sold.

Landscape Capital Management first reported a position in TOVX in Q1 2017 and held it in 1 quarter. The position peaked at $34K in Q1 2017. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

  • Landscape Capital Management reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
  • Landscape Capital Management sold 6 Theriva Biologics shares in Q2 2017, an estimated $34K.
  • Landscape Capital Management first reported a position in Theriva Biologics in Q1 2017 and held it in 1 quarter.
  • Landscape Capital Management's Theriva Biologics position peaked at $34K in Q1 2017.
  • 53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on Landscape Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.